Artificially cloaked viral nanovaccine for cancer immunotherapy
Open Access
- 17 December 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 10 (1), 1-13
- https://doi.org/10.1038/s41467-019-13744-8
Abstract
Virus-based cancer vaccines are nowadays considered an interesting approach in the field of cancer immunotherapy, despite the observation that the majority of the immune responses they elicit are against the virus and not against the tumor. In contrast, targeting tumor associated antigens is effective, however the identification of these antigens remains challenging. Here, we describe ExtraCRAd, a multi-vaccination strategy focused on an oncolytic virus artificially wrapped with tumor cancer membranes carrying tumor antigens. We demonstrate that ExtraCRAd displays increased infectivity and oncolytic effect in vitro and in vivo. We show that this nanoparticle platform controls the growth of aggressive melanoma and lung tumors in vivo both in preventive and therapeutic setting, creating a highly specific anti-cancer immune response. In conclusion, ExtraCRAd might serve as the next generation of personalized cancer vaccines with enhanced features over standard vaccination regimens, representing an alternative way to target cancer.This publication has 64 references indexed in Scilit:
- Oncolytic adenovirusesOncoImmunology, 2012
- Effects of Transport Inhibitors on the Cellular Uptake of Carboxylated Polystyrene Nanoparticles in Different Cell LinesPLOS ONE, 2011
- Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platformProceedings of the National Academy of Sciences of the United States of America, 2011
- Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticlesBiomaterials, 2010
- Current Issues and Future Directions of Oncolytic AdenovirusesMolecular Therapy, 2010
- Anionic Liposomes Increase the Efficiency of Adenovirus-Mediated Gene Transfer to Coxsackie-Adenovirus Receptor Deficient CellsMolecular Pharmaceutics, 2009
- In situ adenovirus vaccination engages T effector cells against cancerVaccine, 2009
- In Vivo Vaccination With Tumor Cell Lysate Plus CpG Oligodeoxynucleotides Eradicates Murine GlioblastomaJournal of Immunotherapy, 2007
- Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunityNature, 2006
- Bilamellar Cationic Liposomes Protect Adenovectors from Preexisting Humoral Immune ResponsesMolecular Therapy, 2002